Related references
Note: Only part of the references are listed.The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma
Michelle Furtado et al.
LEUKEMIA & LYMPHOMA (2016)
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
C. Y. Cheah et al.
ANNALS OF ONCOLOGY (2015)
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy
Martin F. M. de Rooij et al.
BLOOD (2015)
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse
Sophie Bernard et al.
BLOOD (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Targeting Bruton's Tyrosine Kinase With Ibrutinib in B-Cell Malignancies
Y. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Mantle cell lymphoma: evolving management strategies
Elias Campo et al.
BLOOD (2015)
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
Kami Maddocks et al.
BLOOD (2015)
Free factor XIII activation peptide affects factor XIII function
Verena Schroeder et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma
Sophie Bernard et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)
Julie E. Chang et al.
BLOOD (2014)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A. Woyach et al.
BLOOD (2014)
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Jiao Ma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia
Claire V. Hutchinson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Current regimens and novel agents for mantle cell lymphoma
Yiming Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
Xiaohui Zheng et al.
CANCER CELL INTERNATIONAL (2014)
Abstract 2432: The bruton's tyrosine kinase inhibitor ibrutinib synergized with the proteasome inhibitor carfilzomib and overcame immunoproteasome-mediated carfilzomib resistance in mantle cell lymphoma .
Zhishuo Ou et al.
CANCER RESEARCH (2014)
Serum hepcidin following autologous hematopoietic cell transplantation: an illustration of the interplay of iron status, erythropoiesis and inflammation
Aurelie Jaspers et al.
HAEMATOLOGICA (2014)
Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies
Sabine Ponader et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
Anas Younes et al.
LANCET ONCOLOGY (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cobblestone-Area Forming Cells Derived from Patients with Mantle Cell Lymphoma Are Enriched for CD133+ Tumor-Initiating Cells
Daniel J. Medina et al.
PLOS ONE (2014)
Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
Jan A. Burger
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network
C. Y. Cheah et al.
ANNALS OF ONCOLOGY (2013)
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
Richard Delarue et al.
BLOOD (2013)
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
Betty Y. Chang et al.
BLOOD (2013)
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
Girija Dasmahapatra et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappa B
Stuart A. Rushworth et al.
CELLULAR SIGNALLING (2013)
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
Andre Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
Jan A. Burger et al.
LEUKEMIA & LYMPHOMA (2013)
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
Munevver Cinar et al.
LEUKEMIA RESEARCH (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma
Mohand-Akli Boukhiar et al.
EXPERIMENTAL HEMATOLGY & ONCOLOGY (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
Liang Zhang et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
Heather E. Eve et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways
Daniel J. Medina et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang et al.
LANCET ONCOLOGY (2012)
Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling
Chiara Pighi et al.
CELLULAR ONCOLOGY (2011)
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
Jorge E. Romaguera et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma
Fanny Baran-Marszak et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting
Antonina V. Kurtova et al.
BLOOD (2009)
Efficacy and Toxicity of 2 Schedules of Frontline Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Plus Bortezomib in Patients With B-Cell Lymphoma
Vincent Ribrag et al.
CANCER (2009)
Phosphatidylinositol 3′-Kinase Catalytic Subunit α Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma
Amanda Psyrri et al.
CLINICAL CANCER RESEARCH (2009)
Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
Abdalla J. Mohamed et al.
IMMUNOLOGICAL REVIEWS (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase 2 Trial of Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus Methotrexate-Cytarabine for Relapsed or Refractory Aggressive Mantle Cell Lymphoma
Michael Wang et al.
CANCER (2008)
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
Yuhong Zhou et al.
CANCER (2008)
Central nervous system involvement in mantle cell lymphoma
A. Ferrer et al.
ANNALS OF ONCOLOGY (2008)
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
Pedro Jares et al.
NATURE REVIEWS CANCER (2007)
Leukemic involvement is a common feature in mantle cell lymphoma
Ana Ferrer et al.
CANCER (2007)
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma
O. Weigert et al.
LEUKEMIA (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
A Rinaldi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Lymphorna incidence patterns by WHO subtype in the United States, 1992-2001
LM Morton et al.
BLOOD (2006)
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network
M Tiemann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
B cell antigen receptor signaling 101
JM Dal Porto et al.
MOLECULAR IMMUNOLOGY (2004)
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma:: correlation with genomic aberrations, clinical characteristics, and outcome
D Kienle et al.
BLOOD (2003)
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
J Orchard et al.
BLOOD (2003)
Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations
FI Camacho et al.
BLOOD (2003)
Cerebrospinal fluid involvement in mantle cell lymphoma
R Valdez et al.
MODERN PATHOLOGY (2002)